Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens
New York, January 8, 2026, 14:40 EST — Regular session Arcus Biosciences (RCUS) shares slid 9.3% to $21.05 in afternoon trading on Thursday, after earlier touching $22.70. The stock hit a session low of $21.02. Morgan Stanley cut its rating on Arcus to “equal weight” from “overweight” and trimmed its price target to $20 from $23, Investing.com reported, calling the risk-reward more balanced after a strong 2025 run. The Nasdaq Biotechnology Index was down about 2.8%. Investing.com Arcus laid out its 2026 playbook late Wednesday, keeping casdatifan — which it has billed as a potential best-in-class HIF-2a inhibitor, a protein